The burden of opioid-related mortality in the United States
Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. JAMA Network Open. 2018; 1(2):e180217. Epub 2018 Jun 1.
Publications
A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
Antoniou T, Macdonald EM, Yao Z, Gomes T, Tadrous M, Ho JM, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. BMC Musculoskelet Disord. 2018; 19:160. Epub 2018 May 22.
Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study
Pasricha SV, Tadrous M, Khuu W, Juurlink DN, Mamdani MM, Paterson JM, Gomes T. Pain. 2018; 159(8):1562-8. Epub 2018 May 16.
Publicly funded oral chronic hepatitis B treatment patterns in Ontario over 16 years: an ecologic study
Tadrous M, Brahmania M, Martins D, Knowles S, Janssen HLA, Mamdani MM, Juurlink DN, Gomes T. J Manag Care Spec Pharm. 2018; 24(5):464-8. Epub 2018 Apr 26.
Measuring the burden of opioid-related mortality in Ontario, Canada
Gomes T, Greaves S, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. J Addict Med. 2018; 12(5):418-9. Epub 2018 Apr 25.
Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program
Tadrous M, Greaves S, Martins D, Mamdani MM, Juurlink DN, Gomes T. CMAJ Open. 2018; 6(1):E132-8. Epub 2018 Mar 26.
Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: an ecologic study
Tadrous M, Elterman D, Khuu W, Mamdani MM, Juurlink DN, Gomes T. Can Urol Assoc J. 2018; 12(3):E142-5. Epub 2017 Dec 22.
Medication use and kidney cancer survival: a population-based study
Nayan M, Juurlink DN, Austin PC, Macdonald EM, Finelli A, Kulkarni GS, Hamilton RJ; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Int J Cancer. 2018; 142(9):1776-85. Epub 2017 Dec 11.
Prior authorization and Canadian public utilization of direct-acting oral anticoagulants
Gao L, Tadrous M, Knowles S, Mamdani M, Paterson JM, Juurlink D, Gomes T. Healthc Policy. 2017; 13(2):68-78.
Real-world healthcare utilization and effectiveness of omalizumab for the treatment of severe asthma
Tadrous M, Khuu W, Lebovic G, Stanbrook MB, Martins D, Paterson JM, Mamdani MM, Juurlink DN, Gomes T. Ann Allergy Asthma Immunol. 2018; 120(1):59-65.e2. Epub 2017 Oct 3.